Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
On March 10, 2026, NeuroSense Therapeutics Ltd. held a special meeting of shareholders at which investors approved an amendment to the company’s articles of association to increase its registered share capital. This change, formalized in a regulatory filing submitted on March 11, 2026, positions NeuroSense to issue additional shares in the future, potentially enhancing its flexibility to raise funds for operations and growth initiatives, with implications for capital structure and future financing plans.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is an Israel-based biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company is listed in the United States as a foreign private issuer and accesses U.S. capital markets through registration statements to support its research and development programs.
Average Trading Volume: 227,977
Technical Sentiment Signal: Sell
Current Market Cap: $25.79M
Learn more about NRSN stock on TipRanks’ Stock Analysis page.